StockNews.AISignal intelligence
Plexus Corp. · NASDAQ · Technology
Browse public PLXS signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Plexus reported Q1 sales below analyst estimates. Earnings per share of $1.73 surpassed expectations of $1.59. Second-quarter revenue guidance is lower than market estimates. Analysts still rate Plexus as 'Buy' with raised price targets. Plexus shares dropped 10.1% following the earnings announcement.
View signal analysisPlexus reported $960.75 million revenue, down 6% year-over-year. EPS of $1.45 beat consensus estimate of $1.28 by 13.28%. Healthcare revenue slightly surpassed estimates, while Aerospace/Defense grew 24.5%. Industrial revenue declined 5.8%, missing its average estimate. Plexus stock has gained 15.3% over the past month.
View signal analysisPlexus reported Q2 earnings of $1.45, beating estimates by 13.28%. Quarterly revenues missed estimates at $960.75 million, down from $1.02 billion. Earnings outlook shows unfavorable revisions, leading to a Zacks Rank #5. Plexus shares have underperformed the S&P 500 by 6.6% this year. Electronics Manufacturing Services sector ranks in the bottom 22% of Zacks industries.
View signal analysis- Semi-cap subsector shows signs of improvement, while Industrial sector faces inventory corrections. - Plexus Corp. is winning new programs and expanding its funnel in semi-cap sector. - Strong growth in Aerospace and Defense, stability in Health care, and challenges in Industrial sector. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis- Plexus reported earnings of $0.94 per share, beating estimates by 8.05%. - Quarterly revenues were $966.9 million, surpassing estimates by 1.64%. - Company's stock down 10.7% YTD, underperforming the S&P 500 by 6.3%. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis- PLXS to report Q2 2024 results on April 24th. - Estimated revenue decline of 11.2% and EPS decrease of 46.9%. - Anticipates mid-single-digit decline in Healthcare/Life Sciences sector. Price Impact Rating: Bearish Impact Horizon Rating: Short-term Type: Earnings
View signal analysis